Loading…
3 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Aversi-Rational | Pharma | 17.8% | 55th pct | 110 |
| Aversi-Pharma | Pharma | 11.2% | 43rd pct | 110 |
| Natusana | (unclassified) | — | no FY data | 1208 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
Only 2 of 3 peers filed FY2024. Switch to FY2019 (3 of 3).
| Ratio — FY 2024 | Aversi-Pharma | Aversi-Rational | Natusana |
|---|---|---|---|
| Margins | |||
| Gross Margin | 35.9% | 42.7% | — |
| EBITDA Margin | 11.2% | 17.8% | — |
| EBITDAR | 110,275 | 11,367 | — |
| EBITDAR Margin | 11.2% | 17.8% | — |
| EBIT Margin | 6.7% | 17.8% | — |
| Net Profit Margin | 6.4% | 16.4% | — |
| Operating Expense % of Sales | 25.2% | 24.9% | — |
| Returns | |||
| Return on Assets (ROA) | 7.8% | 19.3% | — |
| Return on Equity (ROE) | 12.4% | 39.5% | — |
| ROIC [EBIT / Invested Capital] | 11.7% | 43.1% | — |
| Leverage & debt balances | |||
| Debt-to-Assets | 10.3% | 0.0% | — |
| Debt-to-Equity | 0.16x | 0.00x | — |
| Debt-to-EBITDA | 0.75x | 0.00x | — |
| Equity-to-Assets | 62.9% | 48.9% | — |
| Net Debt | 51,106 | -131 | — |
| Cash & Equivalents | 32,124 | 131 | — |
| Total Debt | 83,230 | N/A | — |
| Liquidity & working capital | |||
| Current Ratio | 1.77x | 1.66x | — |
| Quick Ratio | 0.61x | 1.33x | — |
| Cash Ratio | 0.14x | 0.00x | — |
| Total Current Assets | 399,099 | 43,672 | — |
| Total Current Liabilities | 224,988 | 26,315 | — |
| Inventory | 261,916 | 8,627 | — |
| Trade Receivables | 113,508 | 34,244 | — |
| Trade Payables | 194,442 | 4,348 | — |
| Net Working Capital | 174,111 | 17,358 | — |
| Net Working Capital % of Revenue | 17.8% | 27.2% | — |
| Trade Working Capital | 180,982 | 38,523 | — |
| Trade Working Capital % of Revenue | 18.5% | 60.4% | — |
| Change in Trade Working Capital | N/A | N/A | — |
| Turnover & efficiency | |||
| Inventory Turnover | 2.40x | 4.24x | — |
| Days Inventory Outstanding (DIO) | 152.2 | 86.2 | — |
| Receivables Turnover | 8.64x | 1.86x | — |
| Days Sales Outstanding (DSO) | 42.3 | 196.0 | — |
| Payables Turnover | 3.23x | 8.41x | — |
| Days Payable Outstanding (DPO) | 113.0 | 43.4 | — |
| Cash Conversion Cycle | 81.5 days | 238.7 days | — |
| Asset Turnover | 1.21x | 1.18x | — |
| Cash flow & dividends | |||
| Operating Cash Flow | 84,310 | 4,732 | — |
| Free Cash Flow (OCF − Capex proxy) | 11,960 | 2,622 | — |
| Cash Conversion (OCF / EBITDA) | 76.5% | 41.6% | — |
| Dividends Declared | 7,803 | 5,770 | — |
| Dividend Payout Ratio | 12.3% | 55.1% | — |